Efficacy and toxicity of doxorubicin/cyclophosphamide maintenance therapy in dogs with multicentric lymphosarcoma.
Doxorubicin/cyclophosphamide were evaluated as maintenance drugs for dogs with multicentric lymphosarcoma (n = 28). Median remission time of all dogs was 173 days. Remission duration was shorter, however, in dogs with stage IV/V disease, in dogs with pretreatment hypoalbuminemia, and in dogs that had received glucocorticoids before initiation of chemotherapy (P less than 0.04). Nineteen dogs were evaluable for toxicity. Dose-limiting gastrointestinal toxicosis was observed in three dogs, neutropenia was observed in three dogs, and cardiomyopathy was observed in three dogs. The doxorubicin/cyclophosphamide protocol described in this report is safe and effective in treating canine multicentric lymphosarcoma. Clinical stage, pretreatment steroid therapy, and hypoalbuminemia are prognostic factors for response to this protocol.
Price
G S
GS
Department of Anatomy, College of Veterinary Medicine, North Carolina State University, Raleigh 27606.
Page
R L
RL
Fischer
B M
BM
Levine
J F
JF
Gerig
T M
TM
D000818:Animals; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D003520:Cyclophosphamide / Q000008:administration & dosage; D003967:Diarrhea / Q000139:chemically induced / Q000662:veterinary; D004283:Dog Diseases / Q000139:chemically induced / Q000188:drug therapy*; D004285:Dogs; D004317:Doxorubicin / Q000008:administration & dosage; D005260:Female; D006331:Heart Diseases / Q000139:chemically induced / Q000662:veterinary; D008228:Lymphoma, Non-Hodgkin / Q000188:drug therapy / Q000662:veterinary*; D008297:Male; D009503:Neutropenia / Q000139:chemically induced / Q000662:veterinary; D012074:Remission Induction; D014839:Vomiting / Q000139:chemically induced / Q000662:veterinary
D004317:Doxorubicin; D003520:Cyclophosphamide